EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg

Chaojing Wen, Taiyu He, Guanhua Zha, Aoyi Li, Zhiyi Wang, Zhi Zhou, Dachuan Cai, Dazhi Zhang, Mingli Peng, Xiaofeng Shi, Hong Ren

Frontiers in Cellular and Infection Microbiology · 2026

DOI: 10.3389/fcimb.2026.1803818 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2026. Verfasst von Chaojing Wen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis…. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Interferon alpha-2, Hepatitis B e Antigens, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with low HBsAg levels, HBeAg-negative status and undetectable HBV DNA are recognized as the advantaged population for pegylated interferon α-2b (Peg-IFNα-2b) therapy. However, there are limited reports on the sustainability of HBsAg loss in this population. This study aims to explore the patterns of sustained response following HBsAg clearance in low HBsAg level patients treated with Peg-IFNα-2b through long-term follow-up, providing guidance for clinical practice.

Methods

This retrospective study analyzed patients with baseline HBsAg < 200 IU/mL, HBeAg negativity and undetectable baseline HBV DNA, who achieved HBsAg clearance and received either Peg-IFNα-2b monotherapy or nucleos(t)ide analog (NA) combination therapy. HBV biomarkers and clinical biochemical indicators were assessed during follow-up.

Results

We evaluated sustained HBsAg loss and investigated the risk factors of HBsAg reversion. A total of 203 patients with baseline HBsAg<200IU/ml, HBeAg-negativity and undetectable HBV DNA were enrolled in this study. The median follow-up duration was 96 weeks (range:72 to 120 weeks). 44 (21.67%) patients were observed HBsAg reversion during follow-up, 91.36% (40/44) of which occurred within 96 weeks. Kaplan-Meier stratification analysis revealed that higher end-of-treatment (EOT) HBsAb levels and longer consolidation therapy duration were independently associated with higher sustained HBsAg clearance rates (P< 0.001). Specifically, patients with EOT HBsAb >1000 IU/mL achieved a 100% sustained clearance rate (no reversion observed). Cox regression analysis identified EOT HBsAb levels ≥100 IU/mL (HR = 0.238, P = 0.003)) and consolidation therapy ≥12 weeks (HR = 0.492, P = 0.027) as independent predictor against HBsAg reversion. No ALT flares and adverse events were observed in these HBsAg reverted patients during follow-up, while six patients had detectable HBV DNA.

Conclusion

Low HBsAg and HBeAg negative patients exhibited favorable long-term persistence of HBsAg clearance induced by Peg-IFNα-2b. We identified the EOT HBsAb levels (with levels >1000 IU/mL predicting 100% sustained clearance) and the duration of consolidation therapy as key determinants of long-term treatment success, and proposed 96 weeks as the optimal follow-up time point for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensInterferon alpha-2Hepatitis B e AntigensAntiviral AgentsPolyethylene GlycolsInterferon-alphaHepatitis B, ChronicHumansFemaleRetrospective StudiesRecombinant ProteinsMaleAdultDNA, ViralMiddle AgedTreatment OutcomeHepatitis B virusYoung Adult

Stichwörter der Autor:innen

chronic hepatitis Bfunctional curelow HBsAg levelpegylated interferon α-2bsustained HBsAg clearance

Substanzen

Hepatitis B Surface AntigensInterferon alpha-2peginterferon alfa-2bHepatitis B e AntigensRecombinant ProteinsAntiviral AgentsPolyethylene GlycolsInterferon-alphaDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Diseases, Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute for Viral Hepatitis, the Second Affiliated Hospital, Chongqing Medical University, Chongq…

Zitieren

APA

Wen, C., He, T., Zha, G., Li, A., Wang, Z., Zhou, Z., Cai, D., Zhang, D., Peng, M., Shi, X., & Ren, H. (2026). Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2026.1803818

Vancouver

Wen C, He T, Zha G, Li A, Wang Z, Zhou Z, et al. Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg. Frontiers in Cellular and Infection Microbiology. 2026. doi:10.3389/fcimb.2026.1803818

BibTeX
@article{Wen2026,
  author = {Wen, Chaojing and He, Taiyu and Zha, Guanhua and Li, Aoyi and Wang, Zhiyi and Zhou, Zhi and Cai, Dachuan and Zhang, Dazhi and Peng, Mingli and Shi, Xiaofeng and Ren, Hong},
  title = {Sustained HBsAg clearance induced by pegylated interferon α-2b in HBeAg-negative patients with low baseline HBsAg},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2026},
  doi = {10.3389/fcimb.2026.1803818}
}
Kostenlos starten →